These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9817534)

  • 21. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
    Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The absence of a relation between apolipoprotein E genotypes and the severity of multiple sclerosis in Mexican patients].
    Corona T; Guerrero-Camacho JL; Alonso-Vilatela ME; Flores-Rivera Jde J
    Rev Neurol; 2010 Jan 1-15; 50(1):19-22. PubMed ID: 20073019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disability progression in multiple sclerosis is slower than previously reported.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2006 Jan; 66(2):172-7. PubMed ID: 16434648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HLA-DRB1*15 allele influences the later course of relapsing remitting multiple sclerosis.
    Cournu-Rebeix I; Génin E; Leray E; Babron MC; Cohen J; Gout C; Alizadeh M; Perdry H; Semana G; Brassat D; Clerget-Darpoux F; Yaouanq J; Edan G; Rosenheim M; Fontaine B
    Genes Immun; 2008 Sep; 9(6):570-4. PubMed ID: 18615093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age at disability milestones in multiple sclerosis.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):595-605. PubMed ID: 16415309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy of multiple sclerosis--current practice and future directions.
    Tullman MJ; Lublin FD; Miller AE
    J Rehabil Res Dev; 2002; 39(2):273-85. PubMed ID: 12051470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term survival of patients with multiple sclerosis in West France.
    Leray E; Morrissey S; Yaouanq J; Coustans M; Le Page E; Chaperon J; Edan G
    Mult Scler; 2007 Aug; 13(7):865-74. PubMed ID: 17881399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.
    Miller DH; Albert PS; Barkhof F; Francis G; Frank JA; Hodgkinson S; Lublin FD; Paty DW; Reingold SC; Simon J
    Ann Neurol; 1996 Jan; 39(1):6-16. PubMed ID: 8572668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis?
    Liu C; Playford ED; Thompson AJ
    J Neurol; 2003 Oct; 250(10):1214-8. PubMed ID: 14586605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The natural history of multiple sclerosis.
    Deshpande R; Kremenchutzky M; Rice GP
    Adv Neurol; 2006; 98():1-15. PubMed ID: 16400823
    [No Abstract]   [Full Text] [Related]  

  • 34. The clinical course of multiple sclerosis.
    Confavreux C; Vukusic S
    Handb Clin Neurol; 2014; 122():343-69. PubMed ID: 24507525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple sclerosis: disability and mortality in a cohort of clinically diagnosed patients.
    Citterio A; Azan G; Bergamaschi R; Erbetta A; Cosi V
    Neuroepidemiology; 1989; 8(5):249-53. PubMed ID: 2530458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural history of multiple sclerosis: early prognostic factors.
    Mowry EM
    Neurol Clin; 2011 May; 29(2):279-92. PubMed ID: 21439441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple sclerosis: preventing progression and disability in MS-when to treat?
    Pugliatti M
    Nat Rev Neurol; 2013 Mar; 9(3):129-30. PubMed ID: 23419371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What role does tobacco smoking play in multiple sclerosis disability and mortality? A review of the evidence.
    Weston M; Constantinescu CS
    Neurodegener Dis Manag; 2015; 5(1):19-25. PubMed ID: 25711451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study.
    Minderhoud JM; van der Hoeven JH; Prange AJ
    Acta Neurol Scand; 1988 Jul; 78(1):10-5. PubMed ID: 3176876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.
    Weinshenker BG; Bass B; Rice GP; Noseworthy J; Carriere W; Baskerville J; Ebers GC
    Brain; 1989 Dec; 112 ( Pt 6)():1419-28. PubMed ID: 2597989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.